# US 11,992,475 B1 · Application of Z-ligustilide in resisting rotaviruses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,992,475 B1
- Document ID: US11992475B1
- Status: Granted
- Kind: B1
- Application number: 18/544,621
- Filed: 2023-12-19
- Published: 2024-05-09
- Granted: 2024-05-28
- Earliest claimed: 2023-02-08
- Assignees: Guangdong Medical University
- Applicants: Guangdong Medical University
- Inventors: Lijun Song; Wenchang Zhao
- Web page: https://patentgrep.com/patent/US11992475B1

## CPC

- A61K 31/365: Lactones
- A61P 31/14: for RNA viruses
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention discloses an application of Z-ligustilide in resisting rotaviruses, and relates to the technical field of medicines. Z-ligustilide has no drug toxicity to cells at 60-95 μM and can effectively inhibit rotavirus biosynthesis at 70-85 μM. Z-ligustilide plays a role in resisting rotavirus biosynthesis by inhibiting structural protein VP6, and has no effect of adsorbing and directly killing rotaviruses, which provides a new way for resisting rotaviruses.

## Claims

### Claim 1

A method of inhibiting rotavirus biosynthesis, comprising: providing Z-ligustilide, wherein an effective concentration of the Z-ligustilide is 70-85 μM.

### Claim 2 (depends on 1)

The method of claim 1, wherein the effective concentration of the Z-ligustilide is 80 μM.

### Claim 3 (depends on 1)

The method of claim 1, wherein the step of providing a Z-ligustilide comprises: dissolving a Z-Ligustilide material by adding DMSO (Dimethyl sulfoxide) to obtain a solution, filtering and sterilizing the solution to obtain the Z-ligustilide.